Optimal Duration of DAPT Following Treatment With Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1187 participants.

Also called NCT01325935

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,187 participants (enrolled count) (from the registry)
Sponsor
  • Medtronic Registry lists this organization as a collaborator
Registry
  • NCT NCT01325935
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01325935. Non-randomized; no masking; primary purpose treatment. Start 2011-04 (registry gives no type); primary completion 2013-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Optimal Duration of DAPT Following Treatment With Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese Patients
Acronym
OPERA
Intervention (Drug)
Clopidogrel
Lead sponsor
Associations for Establishment of Evidence in Interventions (class: other)
Collaborator
Medtronic (class: industry)

Record details

Record id
cardio:ct-nct01325935
Content hash
103124797d116dc712f02261ced0aa9c2659f32838e72d133c7f27770256af07